Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16786551 | 1.00 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3ALDH1A1NCF1 | |
| SCHEMBL13388848 | 0.83 | ALDH1A1 (0.35) | ALDH1A1CHRM4CHRM3 | |
| SCHEMBL13544941 | 0.78 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL13544944 | 0.78 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL14593819 | 0.78 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL23269572 | 0.73 | GABRR1 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL19781544 | 0.73 | GABRR1 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL23269569 | 0.73 | EPHX1 (0.38) | SLC6A2SLC6A4SLC6A3ALDH1A1NCF1 | |
| SCHEMBL19781548 | 0.73 | EPHX1 (0.38) | SLC6A2SLC6A4SLC6A3ALDH1A1NCF1 | |
| SCHEMBL23269565 | 0.73 | GABRR1 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944622-B2 | Pyrimidinyl tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160304494-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-10-20 | — | — | US | disclosed |
| US-9394277-B2 | Pyrimidinyl tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150158843-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158843-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | SLC6A2 3363/4885SLC6A4 3909/4885SLC6A3 2454/4885 |
| US-20160304494-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | SLC6A2 3363/4885SLC6A4 3909/4885SLC6A3 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.